{"doi":"10.1016/j.jbc.2025.110390","title":"How short is too short for amyloid fibrils?: Molecular dynamics of oligomers of infectious prion core structures","abstract":"In many proteinopathies, the relative conformations of amyloid fibrils versus smaller oligomers remain unclear. Most tissue-derived isolates of infectious prion protein (PrP) prions are predominantly fibrillar. A few studies have asserted that prion amyloid fibrils efficiently disassemble into dimeric to tetrameric \"elemental bricks\" under certain detergent or chaotropic conditions, but our companion paper provides strong evidence to the contrary. Given our difficulties in isolating detectable amounts of small oligomeric (2-4-mer) prions, we performed molecular dynamics simulations to test the abilities of small fragments (dimers to 25-mers) of cryo-EM-based infectious prion fibril core structures to retain their conformational integrity. We show that dimers of the aRML prion structure lost most of their original secondary and tertiary structure within <<1 μs, while trimers maintained some intermolecular β-sheets. Further increases in fragment size helped preserve major structural motifs and the integrity of the templating surfaces responsible for self-propagation. In simulations of octamers and/or 25-mers, even at elevated temperatures, no fragmentation was observed for aRML, 22L, or 263K prion strains, although the terminal chains were substantially destabilized. Together, our results provide evidence that oligomeric fragments of prion fibril cores as small as tetramers retain substantial structural integrity. Our findings suggest that, as exemplified by PrP fibrils, short cores as small as tetramers may be stable enough to account for bioactive oligomeric species detected in brain extracts from patients with amyloidoses. However, the lack of observed spontaneous core fragmentation suggests that prion oligomers might be rare in vivo and/or produced by non-autonomous physiological cleavage processes.","journal":"Journal of Biological Chemistry","year":2025,"id":521458,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9525,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":826440,"name":"Amitava Roy","orcid":"0000-0002-9100-4108","position":1,"is_corresponding":false},{"id":227561,"name":"Byron Caughey","orcid":"0000-0002-3928-6101","position":2,"is_corresponding":false},{"id":804937,"name":"Efrosini Artikis","orcid":null,"position":0,"is_corresponding":true}],"reference_count":62,"raw_metadata":null,"created_at":"2026-07-19T02:49:44.558743Z","pmid":"40543582","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}